Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2012

Open Access 01-06-2012 | Research article

B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin

Authors: Dimitrios Daoussis, Athanassios C Tsamandas, Stamatis-Nick C Liossis, Ioannis Antonopoulos, Elli Karatza, Georgios Yiannopoulos, Andrew P Andonopoulos

Published in: Arthritis Research & Therapy | Issue 3/2012

Login to get access

Abstract

Introduction

Recently, several studies assessing the clinical efficacy of rituximab (RTX) in systemic sclerosis (SSc) have reported encouraging results. We aimed at exploring whether RTX exerts its beneficial effects on fibrosis through attenuation of platelet-derived growth factor receptor (PDGFR) pathway activation.

Methods

We immunohistochemically assessed skin biopsies obtained from eight patients with SSc prior to and 6 months following RTX treatment, three control SSc patients (at the same time points) and three healthy subjects. We assessed the expression of platelet-derived growth factor, PDGFR and phosphorylated (activated) PDGFR.

Results

We found a strong correlation of PDGFRα and PDGFRβ expression on spindle-like cells and collagen deposition in SSc biopsies (r = 0.97 and r = 0.96 for PDGFRα and PDGFRβ, respectively; P < 0.0001 for both), indicating a strong link between PDGFR expression and fibrosis. Expression of PDGFRα and PDGFRβ in the papillary dermis significantly decreased following RTX administration (mean ± standard error of the mean at baseline vs. 6 months, respectively: PDGFRα, 42.05 ± 5.03 vs. 26.85 ± 3.00, P = 0.004; and PDGFRβ, 37.14 ± 4.94 vs. 24.01 ± 3.27, P = 0.012). Similarly, expression of phosphorylated PDGFRα and PDGFRβ in the papillary dermis significantly decreased following RTX administration (P = 0.006 and P = 0.013 for phospho-PDGFRα and phospho-PDGFRβ, respectively). No changes in platelet-derived growth factor tissue expression or serum levels were found following RTX treatment.

Conclusion

RTX may favorably affect skin fibrosis through attenuation of PDGFR expression and activation, a finding that supports a disease-modifying role of RTX in SSc. Large-scale, multicenter studies are needed to further explore the efficacy of RTX in SSc.
Appendix
Available only for authorised users
Literature
1.
go back to reference Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP: Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010, 49: 271-280. 10.1093/rheumatology/kep093.CrossRef Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP: Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010, 49: 271-280. 10.1093/rheumatology/kep093.CrossRef
2.
go back to reference Bosello S, De Santis M, Lama G, Spano C, Angelucci C, Tolusso B, Sica G, Ferraccioli G: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010, 12: R54-10.1186/ar2965.PubMedCentralCrossRefPubMed Bosello S, De Santis M, Lama G, Spano C, Angelucci C, Tolusso B, Sica G, Ferraccioli G: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010, 12: R54-10.1186/ar2965.PubMedCentralCrossRefPubMed
3.
go back to reference Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW: B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009, 60: 578-583. 10.1002/art.24249.PubMedCentralCrossRefPubMed Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW: B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009, 60: 578-583. 10.1002/art.24249.PubMedCentralCrossRefPubMed
4.
go back to reference Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, De Keyser F: Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010, 69: 193-197. 10.1136/ard.2008.095463.CrossRefPubMed Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, De Keyser F: Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010, 69: 193-197. 10.1136/ard.2008.095463.CrossRefPubMed
5.
go back to reference Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF: B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol. 2006, 169: 954-966. 10.2353/ajpath.2006.060205.PubMedCentralCrossRefPubMed Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF: B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol. 2006, 169: 954-966. 10.2353/ajpath.2006.060205.PubMedCentralCrossRefPubMed
6.
go back to reference Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest. 2002, 109: 1453-1462.PubMedCentralCrossRefPubMed Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest. 2002, 109: 1453-1462.PubMedCentralCrossRefPubMed
7.
go back to reference Asano N, Fujimoto M, Yazawa N, Shirasawa S, Hasegawa M, Okochi H, Tamaki K, Tedder TF, Sato S: B lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol. 2004, 165: 641-650. 10.1016/S0002-9440(10)63328-7.PubMedCentralCrossRefPubMed Asano N, Fujimoto M, Yazawa N, Shirasawa S, Hasegawa M, Okochi H, Tamaki K, Tedder TF, Sato S: B lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol. 2004, 165: 641-650. 10.1016/S0002-9440(10)63328-7.PubMedCentralCrossRefPubMed
8.
go back to reference Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S: CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol. 2008, 172: 1650-1663. 10.2353/ajpath.2008.071049.PubMedCentralCrossRefPubMed Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S: CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol. 2008, 172: 1650-1663. 10.2353/ajpath.2008.071049.PubMedCentralCrossRefPubMed
9.
go back to reference Komura K, Yanaba K, Horikawa M, Ogawa F, Fujimoto M, Tedder TF, Sato S: CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum. 2008, 58: 3574-3584. 10.1002/art.23995.CrossRefPubMed Komura K, Yanaba K, Horikawa M, Ogawa F, Fujimoto M, Tedder TF, Sato S: CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum. 2008, 58: 3574-3584. 10.1002/art.23995.CrossRefPubMed
10.
go back to reference Bonner JC: Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004, 15: 255-273. 10.1016/j.cytogfr.2004.03.006.CrossRefPubMed Bonner JC: Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004, 15: 255-273. 10.1016/j.cytogfr.2004.03.006.CrossRefPubMed
11.
go back to reference Yi ES, Lee H, Yin S, Piguet P, Sarosi I, Kaufmann S, Tarpley J, Wang NS, Ulich TR: Platelet-derived growth factor causes pulmonary cell proliferation and collagen deposition in vivo. Am J Pathol. 1996, 149: 539-548.PubMedCentralPubMed Yi ES, Lee H, Yin S, Piguet P, Sarosi I, Kaufmann S, Tarpley J, Wang NS, Ulich TR: Platelet-derived growth factor causes pulmonary cell proliferation and collagen deposition in vivo. Am J Pathol. 1996, 149: 539-548.PubMedCentralPubMed
12.
go back to reference Hoyle GW, Li J, Finkelstein JB, Eisenberg T, Liu JY, Lasky JA, Athas G, Morris GF, Brody AR: Emphysematous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor. Am J Pathol. 1999, 154: 1763-1775. 10.1016/S0002-9440(10)65432-6.PubMedCentralCrossRefPubMed Hoyle GW, Li J, Finkelstein JB, Eisenberg T, Liu JY, Lasky JA, Athas G, Morris GF, Brody AR: Emphysematous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor. Am J Pathol. 1999, 154: 1763-1775. 10.1016/S0002-9440(10)65432-6.PubMedCentralCrossRefPubMed
13.
go back to reference Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006, 354: 2667-2676. 10.1056/NEJMoa052955.CrossRefPubMed Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006, 354: 2667-2676. 10.1056/NEJMoa052955.CrossRefPubMed
14.
go back to reference Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980, 23: 581-590. 10.1002/art.1780230510.CrossRef Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980, 23: 581-590. 10.1002/art.1780230510.CrossRef
15.
go back to reference Daoussis D, Liossis SN, Tsamandas A, Kalogeropoulou C, Paliogianni F, Sirinian C, Yiannopoulos G, Andonopoulos AP: Effect of long term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2011 Daoussis D, Liossis SN, Tsamandas A, Kalogeropoulou C, Paliogianni F, Sirinian C, Yiannopoulos G, Andonopoulos AP: Effect of long term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2011
16.
go back to reference Tsamandas AC, Thomopoulos K, Zolota V, Kourelis T, Karatzas T, Ravazoula P, Tepetes K, Petsas T, Karavias D, Karatza C, Bonikos DS, Gogos C: Potential role of bcl-2 and bax mRNA and protein expression in chronic hepatitis type B and C: a clinicopathologic study. Mod Pathol. 2003, 16: 1273-1288. 10.1097/01.MP.0000097367.56816.5E.CrossRefPubMed Tsamandas AC, Thomopoulos K, Zolota V, Kourelis T, Karatzas T, Ravazoula P, Tepetes K, Petsas T, Karavias D, Karatza C, Bonikos DS, Gogos C: Potential role of bcl-2 and bax mRNA and protein expression in chronic hepatitis type B and C: a clinicopathologic study. Mod Pathol. 2003, 16: 1273-1288. 10.1097/01.MP.0000097367.56816.5E.CrossRefPubMed
17.
go back to reference Vis AN, Kranse R, Nigg AL, van der Kwast TH: Quantitative analysis of the decay of immunoreactivity in stored prostate needle biopsy sections. Am J Clin Pathol. 2000, 113: 369-373. 10.1309/CQWY-E3F6-9KDN-YV36.CrossRefPubMed Vis AN, Kranse R, Nigg AL, van der Kwast TH: Quantitative analysis of the decay of immunoreactivity in stored prostate needle biopsy sections. Am J Clin Pathol. 2000, 113: 369-373. 10.1309/CQWY-E3F6-9KDN-YV36.CrossRefPubMed
18.
go back to reference Hatanaka Y, Hashizume K, Kamihara Y, Itoh H, Tsuda H, Osamura RY, Tani Y: Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest™ in breast carcinoma by image analysis. Pathol Int. 2001, 51: 33-36. 10.1046/j.1440-1827.2001.01162.x.CrossRefPubMed Hatanaka Y, Hashizume K, Kamihara Y, Itoh H, Tsuda H, Osamura RY, Tani Y: Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest™ in breast carcinoma by image analysis. Pathol Int. 2001, 51: 33-36. 10.1046/j.1440-1827.2001.01162.x.CrossRefPubMed
19.
go back to reference Olson LE, Soriano P: Increased PDGFRα activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell. 2009, 16: 303-313. 10.1016/j.devcel.2008.12.003.PubMedCentralCrossRefPubMed Olson LE, Soriano P: Increased PDGFRα activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell. 2009, 16: 303-313. 10.1016/j.devcel.2008.12.003.PubMedCentralCrossRefPubMed
20.
go back to reference Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Grone HJ, Lipson KE, Huber PE: Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005, 201: 925-935. 10.1084/jem.20041393.PubMedCentralCrossRefPubMed Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Grone HJ, Lipson KE, Huber PE: Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005, 201: 925-935. 10.1084/jem.20041393.PubMedCentralCrossRefPubMed
21.
go back to reference Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE: Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007, 29: 976-985. 10.1183/09031936.00152106.CrossRefPubMed Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE: Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007, 29: 976-985. 10.1183/09031936.00152106.CrossRefPubMed
22.
go back to reference Rice AB, Moomaw CR, Morgan DL, Bonner JC: Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol. 1999, 155: 213-221. 10.1016/S0002-9440(10)65115-2.PubMedCentralCrossRefPubMed Rice AB, Moomaw CR, Morgan DL, Bonner JC: Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol. 1999, 155: 213-221. 10.1016/S0002-9440(10)65115-2.PubMedCentralCrossRefPubMed
23.
go back to reference Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JH: Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009, 60: 219-224. 10.1002/art.24186.CrossRefPubMed Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JH: Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009, 60: 219-224. 10.1002/art.24186.CrossRefPubMed
24.
go back to reference Gay S, Jones RE, Huang GQ, Gay RE: Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol. 1989, 92: 301-303. 10.1111/1523-1747.ep12276895.CrossRefPubMed Gay S, Jones RE, Huang GQ, Gay RE: Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol. 1989, 92: 301-303. 10.1111/1523-1747.ep12276895.CrossRefPubMed
25.
go back to reference Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, Leroy EC, Sutherland S, Silver RM: Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol. 1995, 22: 1876-1883.PubMed Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, Leroy EC, Sutherland S, Silver RM: Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol. 1995, 22: 1876-1883.PubMed
26.
go back to reference Pandolfi A, Florita M, Altomare G, Pigatto P, Donati MB, Poggi A: Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis. Proc Soc Exp Biol Med. 1989, 191: 1-4.CrossRefPubMed Pandolfi A, Florita M, Altomare G, Pigatto P, Donati MB, Poggi A: Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis. Proc Soc Exp Biol Med. 1989, 191: 1-4.CrossRefPubMed
27.
go back to reference Klareskog L, Gustafsson R, Scheynius A, Hallgren R: Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum. 1990, 33: 1534-1541. 10.1002/art.1780331011.CrossRefPubMed Klareskog L, Gustafsson R, Scheynius A, Hallgren R: Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum. 1990, 33: 1534-1541. 10.1002/art.1780331011.CrossRefPubMed
28.
go back to reference Zheng XY, Zhang JZ, Tu P, Ma SQ: Expression of platelet-derived growth factor B-chain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma. J Dermatol Sci. 1998, 18: 90-97. 10.1016/S0923-1811(98)00027-9.CrossRefPubMed Zheng XY, Zhang JZ, Tu P, Ma SQ: Expression of platelet-derived growth factor B-chain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma. J Dermatol Sci. 1998, 18: 90-97. 10.1016/S0923-1811(98)00027-9.CrossRefPubMed
29.
go back to reference Soria A, Cario-Andre M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taieb A: The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology. 2008, 216: 109-117. 10.1159/000111507.CrossRefPubMed Soria A, Cario-Andre M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taieb A: The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology. 2008, 216: 109-117. 10.1159/000111507.CrossRefPubMed
30.
go back to reference Jordan S, Distler J, Maourer B, Allanore Y, van Laar J, Distler O: Safety and efficacy of Rituximab in SSC: an analysis from the European Trial and Research Group. Proceedings of the 2nd Systemic Sclerosis World Congress; February 2-4 2012; Madrid, Spain. 2012, Rheumatology, UK, 51 (Supplement 2): ii25- Jordan S, Distler J, Maourer B, Allanore Y, van Laar J, Distler O: Safety and efficacy of Rituximab in SSC: an analysis from the European Trial and Research Group. Proceedings of the 2nd Systemic Sclerosis World Congress; February 2-4 2012; Madrid, Spain. 2012, Rheumatology, UK, 51 (Supplement 2): ii25-
Metadata
Title
B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin
Authors
Dimitrios Daoussis
Athanassios C Tsamandas
Stamatis-Nick C Liossis
Ioannis Antonopoulos
Elli Karatza
Georgios Yiannopoulos
Andrew P Andonopoulos
Publication date
01-06-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3879

Other articles of this Issue 3/2012

Arthritis Research & Therapy 3/2012 Go to the issue